Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$79.29 USD

79.29
1,466,257

-1.20 (-1.49%)

Updated Nov 7, 2024 03:59 PM ET

After-Market: $79.32 +0.03 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

CVS Health (CVS) Q2 Earnings Top Estimates, 2020 View Up

by Zacks Equity Research

CVS Health's (CVS) Health Care Benefits segment registers membership growth in Q2.

Intersect ENT (XENT) Q2 Loss Widens, Revenues Beat Estimates

by Zacks Equity Research

Although Intersect ENT's (XENT) Q2 sales are down year over year, it's stronger than expected, led by the return of sinus surgery procedures using PROPEL.

Haemonetics (HAE) Q1 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Haemonetics' (HAE) first-quarter fiscal 2021 results reflect impressive performance by Blood Center segment despite dismal overall performance during the coronavirus-led crisis.

QIAGEN (QGEN) Q2 Earnings In Line With Estimates, Margins Up

by Zacks Equity Research

QIAGEN (QGEN) registered robust revenue growth across majority of geographies and both operating segments in Q2 despite the coronavirus-led economic crisis.

Zimmer Biomet's (ZBH) Q2 Earnings Beat, Margins Contract

by Zacks Equity Research

Zimmer Biomet's (ZBH) second-quarter elective procedure volumes decline across all regions.

Bruker (BRKR) Q2 Earnings Surpass Estimates, Margins Fall

by Zacks Equity Research

Bruker's (BRKR) second-quarter 2020 results reflect dismal performance by all segments and geographies due to coronavirus-led business disruptions.

Henry Schein (HSIC) Q2 Earnings Top Estimates, Margins Dip

by Zacks Equity Research

Henry Schein (HSIC) sees dismal segmental performance in Q2 due to disruptions resulting from the coronavirus pandemic.

STERIS' (STE) Earnings & Revenues Surpass Estimates in Q1

by Zacks Equity Research

STERIS' (STE) first-quarter fiscal 2021 results reflect strong performance by the Life Sciences segment despite the coronavirus-led economic crisis.

Hologic (HOLX) Q3 Earnings Surpass Estimates, Margins Rise

by Zacks Equity Research

Hologic (HOLX) exhibited robust segmental growth in third-quarter fiscal 2020 driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.

Hologic (HOLX) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Hologic (HOLX) delivered earnings and revenue surprises of 108.33% and 37.11%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

T2 Biosystems (TTOO) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

T2 Biosystems' (TTOO) second-quarter results are likely to reflect growth in product revenues.

Invitae (NVTA) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Genetic testing is likely to drive Invitae's (NVTA) Q2 earnings.

Aphria (APHA) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Aphria's (APHA) fiscal fourth-quarter results are likely to reflect higher sales from medical and adult-use cannabis products.

Stryker (SYK) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Stryker's (SYK) second-quarter results are likely to reflect weak segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.

Baxter (BAX) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Baxter's (BAX) second-quarter performance is likely to reflect growth in its five global business units.

DaVita (DVA) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Solid performance within net dialysis and related lab patient service segment is likely to have contributed to DaVita's (DVA) top line in Q2.

Cerner (CERN) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Cerner's (CERN) second-quarter results are likely to reflect solid show by Subscriptions, Managed Services and Licensed software segments.

DexCom (DXCM) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

DexCom's (DXCM) second-quarter results are likely to reflect rising global awareness of its real-time CGM.

Quidel (QDEL) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Quidel (QDEL) is likely to have witnessed an uptick in rapid immunoassay revenues in Q2.

PerkinElmer (PKI) to Post Q2 Earnings: What's in the Cards?

by Zacks Equity Research

PerkinElmer's (PKI) second-quarter results are likely to reflect strong performance at Diagnostics segment. However, forex remained a woe.

Ecolab (ECL) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Ecolab's (ECL) Global Industrial segment is likely to have gained from the Water, Food & Beverage and Life Sciences sub-units in Q2.

Hologic (HOLX) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Diagnostics Aid Hologic (HOLX) Q3 Earnings Amid Coronavirus?

by Zacks Equity Research

Strength in segmental business is likely to have aided Hologic's (HOLX) performance in third-quarter fiscal 2020 amid the coronavirus-led economic doldrums.

Hologic Expands Product Portfolio With New Ultrasound System

by Zacks Equity Research

Hologic's (HOLX) latest cart-based ultrasound system enhances efficiency and accuracy to better meet the requirements of breast imagers and optimize patient care.

Myriad Genetics Rides on EndoPredict Amid Coronavirus Crisis

by Zacks Equity Research

Myriad Genetics (MYGN) expects to register an uptick in hereditary cancer volumes on account of its contract with UnitedHealthcare.